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Lewy body diseasesPrior work has shown that functional connectivity between themidbrain and putamen is altered in patientswith
impairments in the dopamine system. This study examines whether individual differences in midbrain–striatal
connectivity are proportional to the integrity of the dopamine system in patients with nigrostriatal dopamine
loss (Parkinson3s disease and dementia with Lewy bodies). We assessed functional connectivity of the putamen
during resting state fMRI and dopamine transporter (DAT) availability in the striatumusing 11C-Altropane PET in
twenty patients. In line with the hypothesis that functional connectivity between themidbrain and the putamen
reﬂects the integrity of the dopaminergic neurotransmitter system, putamen–midbrain functional connectivity
was signiﬁcantly correlated with striatal DAT availability even after stringent control for effects of head motion.
DAT availability did not relate to functional connectivity between the caudate and thalamus/prefrontal areas. As
such, resting state functional connectivity in themidbrain–striatal pathwaymay provide a useful indicator of un-
derlying pathology in patients with nigrostriatal dopamine loss.
© 2015 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).1. Introduction
Dopamine cells of the midbrain (substantia nigra and ventral teg-
mental area) heavily innervate the striatum. Loss of dopaminergic
cells in the midbrain is a neuropathological hallmark of age-related
Lewy body diseases (LBD) including Parkinson3s disease with or with-
out dementia and dementia with Lewy bodies. Nigrostriatal dopamine
loss can currently only be measured in vivo using positron emission
tomography (PET). Striatal dopamine transporter (DAT) availabilitymea-
sured with PET is one measure of nigrostriatal integrity (see Brooks and
Pavese, 2011, for review). DAT binding in putamen and caudate in pa-
tients with LBD is reduced by 55–75% compared to age-matched
controls (Innis et al., 1993; O3Brien et al., 2004) and correlates with
nigrostriatal neuron loss observed post-mortem (Colloby et al., 2012).
Consistent with known projections, the striatum and midbrain are
functionally coupled as measured with functional magnetic resonance
imaging (fMRI) during resting state in healthy adults (Kelly et al.,ine transporter;UPDRS,Uniﬁed
VR, distribution volume ratio.
thinoula A. Martinos Center for
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A. Van Dijk).
. This is an open access article under2009; Hacker et al., 2012). Studies in patients with Parkinson3s disease
have shown that midbrain–putamen functional connectivity is reduced
compared to age-matched healthy controls (Hacker et al., 2012; Wu
et al., 2012), suggesting that loss of striatal resting-state functional con-
nectivity may be reﬂective of the nigrostriatal dopamine loss in these pa-
tients. In line with this hypothesis, Tomasi and Volkow (2014) showed
increases inmidbrain couplingwith ventral striatumandpallidum in chil-
dren with attention deﬁcit hyperactivity disorder (ADHD), which may
parallel the increased levels of markers of the dopamine system that are
seen in ADHD (e.g. Spencer et al., 2013). In schizophrenic patients, mid-
brain connectivity with ventral striatum was decreased (Hadley et al.,
2014), again possibly reﬂecting altered functions of the dopamine system
in this patient group (Laruelle et al., 1996).
To date, however, reports have been restricted to group comparisons
between patient groups with known pathology of the dopamine sys-
tem, without an analysis of individual differences in midbrain–striatal
connectivity in relation to in vivo assessments of dopamine PET
markers. The present study was designed to ﬁll this gap by assessing
striatal connectivity with resting-state fMRI and DAT availability with
PET in the same group of patients with nigrostriatal dopamine loss.
We predicted that weaker functional connectivity MRI between the
midbrain and the putamen would be related to lower presynaptic DAT
availability in the striatum. If present, such a result would indicatethe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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biomarker of underlying neuropathology.
2. Materials and methods
2.1. Participants
Twenty-six patients (mean age=68.1 years, SD=6.7, range 57–81,
9 female)with parkinsonismcompleted a PET scan, a structuralMRI and
at least one resting-state fMRI run. Data from six of these patients were
excluded from analysis because of head motion (Van Dijk et al., 2012).
Subjects were recruited from the MGH Movement Disorders and
Memory Disorders Units. All subjects gave informed consent to partici-
pate in the study according to the protocol approved by the ethical re-
view board. Patients were clinically diagnosed with parkinsonism and
had, on average, experienced motor symptoms for 9.2 years (SD =
5.6, range 3–22 years). Fourteen patients met diagnostic criteria for
idiopathic Parkinson3s disease (Hughes et al., 1992) and were non-
demented. Six other patients were diagnosed with parkinsonism and
cognitive impairment: three had dementia with Lewy bodies
(McKeith et al., 2005) and three had Parkinson3s disease with dementia
(Emre et al., 2007). Although it is worthwhile to study these patient
groups separately when large sample sizes permit (e.g. Marquie et al.,
2014), in the current study the primary objective was to study striatal
functional connectivity in relation to dopamine loss as measured with
PET. As all subjects shared the typical motor signs of parkinsonism,
and as DAT density was depleted in all patients relative to a healthy ref-
erence sample, patients were treated as a single group.
Patients were tested on their prescribed dopamine replacement
medication to minimize head motion and a levodopa equivalent dose
was calculated (mean = 400.3 mg/day, SD = 376.8; Tomlinson et al.,
2010). Motor impairment was classiﬁed according to Hoehn and Yahr
criteria (mean= 2.5, SD= 0.6, range 2–4) and the Uniﬁed Parkinson3s
Disease Rating Scale motor subscale (UPDRS; mean = 20.7, SD = 8.4,
range 8–37; data missing for one individual).
Data from twenty-nine clinically normal older adults were used as
reference sample to (1) demonstrate that our PET measure accurately
separates DAT densities in clinically normal aging from pathological do-
pamine loss and (2) to identify reference seeds for the functional con-
nectivity analyses. Control subjects were clinically normal older adults
(mean=70.9 years, range 63–80, 11 females) recruited for the Harvard
Aging Brain study. Patients andnormal controls did not differ in terms of
age (t(47) = 1.0, p = 0.34) or estimated VIQ (mean(±SD) patients =
122.5(11.4), mean(±SD) controls = 120.9(9.6); t(46) = −0.5, p =
0.62; based on the American National Reading Test; Ryan and Paolo,
1992). Healthy controls were slightly lower in years of education
(mean(±SD) patients = 16.2(3.2), mean(±SD) controls = 14.4(2.8);
t(47) =−2.1, p = 0.04). Data from these patients and normal control
participants have been presented elsewhere (Marquie et al., 2014;
Schultz et al., 2014; Shaw et al., 2015).
2.2. PET acquisition and analysis
Binding of 11C-Altropane, a ligand with high selectivity for striatal
DAT (Fischman et al., 2001), was assessed with an HR+ (CTI, Knoxville,
TN) PET camera (3D mode, 63 adjacent slices of 2.42 mm interval,
15.2 cm axial ﬁeld of view, 5.60 mm transaxial resolution).
Approximately 15 mCi of 11C-Altropane was intravenously adminis-
tered as a bolus over 20–30 s. Dynamic images were acquired in 39
frames of increasing duration for a total of 60 min (8 × 5 s, 4 × 1 min,
27 × 2 min). PET data were reconstructed using a ﬁltered back-
projection algorithm and standard photon attenuation measurements
were used to correct the emission data. The participant3s head was sta-
bilized during the scan and correction for residual headmotionwas per-
formed on the dynamic data to a common reference frame.PET data were partial volume corrected using an anatomical MRI-
based correction method, implemented using PVElab Software and
SPM5 (Quarantelli et al., 2004; Meltzer et al., 1990). Then, uptake im-
ages (averaged across the ﬁrst 8 min) were normalized to the SPM8
standard PET template in MNI space using a two-step procedure of an
initial 12-parameter afﬁne transformation followed by non-linear
warping (http://www.ﬁl.ion.ucl.ac.uk/spm). Normalization parameters
were applied to the remaining frames and a striatum region of interest
(ROI) was deﬁned as the 1000 voxels (=8 cm3) with the highest signal
intensity on the average emission image (8–60min, Fig. 1A). The search
was constrained to a large search area around the striatum. A central
cerebellar region of 1000 voxels was deﬁned in MNI atlas space as a
reference region and Logan graphical analysis was used to derive distri-
bution volume ratios (DVRs; Logan et al., 1990) for the striatum. Alter-
native methods for PET ROI delineation of striatum involve manual or
automatic delineation in native PET or MRI space. However, anatomical
ROI estimates can be inaccurate due to low spatial resolution or low
contrast and also differ in size between individuals, which may intro-
duce dependencies between volume measures and DVR. Our approach
ensured that DVR estimation for the striatum is fully automated, of a
ﬁxed size, and not affected by moderate errors in the registration to
standard space. Even though this approach does not distinguish be-
tween sub-regions of the striatum it accurately separates DAT densities
in clinically normal aging (mean = 3.38, SD = 0.34) from pathological
dopamine loss in the patients (mean = 2.02, SD = 0.29; t(47) =
14.70, p b 0.01; Fig. 1B) and the DVR estimates correlated signiﬁcantly
with disease duration (r = −0.45, p = 0.02) and Hoehn–Yahr stage
of motor impairment (r =− 0.45, p = 0.03) in the present sample.2.3. MRI acquisition and analysis
All patients completed a T1-weighted MPRAGE scan (1.0 mm
isotropic voxel size, TR = 2300 ms, TE = 2.98 ms, Flip angle 9 deg,
192 slices) and at least one resting state fMRI run of 6 min and 30 s
using a T2*-weighted sequence sensitive to blood oxygenation level de-
pendent contrast (2.0 mm isotropic voxel size; TR = 5000 m, TE =
30 ms, ﬂip angle 90 deg, 55 slices). For normal controls, a multiecho
MPRAGE (1.20 mm isotropic voxel size, TR = 2200 ms, TI = 1100 ms,
Flip angle = 7 deg, 4× acceleration, 144 slices, TE = 1.54, 3.36, 5.18,
7.01 ms) and two resting state fMRI runs of 6 min and 20 s were avail-
able (3.0 mm isotropic voxel size, TR = 3000 ms, TE = 30 ms, Flip
angle = 85 deg, 47 slices). All MRI scans were acquired on a Siemens
3 T Tim Trio scanner at Massachusetts General Hospital.
From the T1-weighted structural scan, ventricular size was estimat-
ed from a volumetric segmentation using Freesurfer (v 5.1.0, e.g. Fischl
et al., 2002). Ventricle volume was normalized by intracranial volume
following the methods described in Buckner et al. (2004), and used to
control for the effects of subcortical atrophy in the association between
functional connectivity and striatal DVR.
Pre-processing of the fMRI data followed the procedures of prior
studies in this ﬁeld (di Martino et al., 2008; Hacker et al., 2012) and
included slice-timing correction, motion-correction, registration to
standard MNI152 space, spatial smoothing, temporal ﬁltering, and
intensity normalization. Motion-correction was performed using rigid
body translation and rotation of all volumes to the ﬁrst volume
(Jenkinson et al., 2002). To acquire a summary measure of motion, the
root-mean-square of the 3 translation and 3 rotation parameters was
calculated for each volume relative to the preceding volume and aver-
aged over all volumes of the scan. Following this step, six patients
were excluded from further analysis (N = 20 remaining) because
they had an average mean displacement of more than 0.25 mm,
where 0.25mm corresponds approximately to 2 SDs above the average
mean motion for the healthy older control group (mean = 0.10 mm,
SD = 0.07), and/or at least 5 isolated movements of more than
0.5 mm from one brain volume as compared to the previous volume.
Fig. 1. A) An example image of 11-C Altropane binding is shown for a normal control and a patient with Parkinson3s disease. The striatal ROI was identiﬁed as the 1000 voxels with peak
radioactivity uptake. B) Striatal DAT availability (11C-Altropane DVR) is signiﬁcantly lower in patients with nigrostriatal dopamine loss (dementia with Lewy bodies and Parkinson3s dis-
ease) compared with age-matched normal control participants (NC).
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other sources of variance unlikely to represent signal of neuronal origin
(global signal, cerebrospinal ﬂuid signal, deep cerebral white matter sig-
nal and the ﬁrst temporal derivatives of these waveforms; Van Dijk
et al., 2010)were removed by regression, saving the residual timecourses
for each voxel for further analysis.
Bilateral caudate and putamen ROIs were deﬁned based on the
volumetric segmentation and co-registered to the fMRI data using
boundary-based registration (Greve and Fischl, 2009) followed by reg-
istration to standardMNI152 space. In a ﬁrst step, the putamen seed re-
gionwas further separated into hemispheres and anterior and posterior
putamen (cf Hacker et al., 2012 for details). However, connectivity from
all four putamen subregions converged on a highly similar bilateral
target in midbrain. Therefore, connectivity from the putamen to theFig. 2. Putamen and caudate seedswere deﬁned based on anatomy from the individual subject s
functional connectivityMRImapsusing theputamenand caudate as seed regionwere then calcu
thepatients. ROIswere identiﬁedas peak connectivity estimates of known regionswithin the ca
network we selected peaks in the right and left midbrain (MNI coordinates right x = 10, y =−
coordinates right x=36, y=−26, z= 68, left x=−34, y=−20, z=68). For the caudate net
z = 6) and right and left anterior thalamus (MNI coordinates right x = 10, y =−2, z = 6, lefmidbrain target ROI was functionally deﬁned based on average whole-
brain correlation using the entire putamen. Peak coordinates of mid-
brain connectivity in the healthy controls were identiﬁed at (right/
left) x = 10/−8, y = −8/−10, z = −12/−12 and a 6 mm sphere
was added to capture individual variation around the peak. This ROI
converges spatially with the substantia nigra ROI identiﬁed by Tomasi
and Volkow (2014) (x =±12, y =−12, z =−12).
We also found the putamen to be negatively correlated with the
sensori-motor cortex and included these targets in the analysis. Control
targets for which we did not expect an associationwith DAT availability
in LBD were functionally deﬁned targets on average whole-brain corre-
lation maps of the caudate seed (thalamus and anterior cingulate cor-
tex; di Martino et al., 2008; Hacker et al., 2012). All a-priori deﬁned
ROIs from the normal controls (Fig. 2) were then applied to the patienttructural MRI. Example putamen and caudate ROIs for one subject are shown.Whole-brain
lated in 29 clinically normal older adults to deﬁne regions of interest for further analyses in
udate andputamennetworks (DiMartino et al., 2008; Hacker et al., 2012). For theputamen
8, z =−12, left x =−8, y =−10, z =−12) and right and left postcentral gyrus (MNI
workwe included peaks in the anterior cingulate cortex (MNI coordinates x=−2, y= 46,
t x =−10, y =−4, z = 8).
Table 1
Linear regression of Altropane DVR on connectivity with covariates listed in parentheses.
Outcome (fcMRI) Predictors Beta p
Putamen−midbrain Altropane DVR 0.52 0.03
Altropane DVR(H & Y) 0.50 0.07
Altropane DVR(Levodopa dose) 0.32 0.17
Altropane DVR(Age) 0.45 0.08
Altropane DVR(Subcortical atrophy) 0.69 0.04
Putamen−postcentral
gyrus
Altropane DVR −0.50 0.04
Altropane DVR(H & Y) −0.33 0.16
Altropane DVR(Levodopa dose) −0.36 0.14
Altropane DVR(Age) −0.78 b0.01
Altropane DVR(Subcortical atrophy) −0.68 0.04
H & Y — Hoehn and Yahr clinical stage.
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(1) putamen and midbrain, (2) putamen and sensori-motor cortex
(postcentral gyrus), (3) caudate and anterior cingulate, and (4) caudate
and anterior thalamuswere calculated. Since ourmain hypothesiswas a
positive association betweenmidbrain–putamen functional connectivi-
ty and striatal DAT availability within this patient group, the main anal-
ysis consisted of Pearson3s correlations and linear regression between
fMRI functional connectivity and striatal PET DAT signal at a signiﬁcance
threshold of p b 0.05 (1-tailed). In an additional analysis we also
explored the correlations between DAT availability and functional con-
nectivity in the reference sample of healthy controls. These latter results
should be interpreted cautiously, however, because these data are not
independent from those used to deﬁne the seeds. Direct comparisons
between patients and healthy controls were not computed because of
differences in the fMRI acquisitions.
3. Results
Of chief interest, putamen–midbrain functional connectivity was as-
sociated with striatal DAT availability such that weaker connectivity
was related to lower DAT signal (r = 0.38, p = 0.05, Fig. 3). Lower
Altropane DVR was also associated with a less negative correlation be-
tween the putamen and the postcentral gyrus (r =−0.37, p = 0.05;
Fig. 3). Striatal DAT availability was not related to functional connectiv-
ity between the caudate and the anterior cingulate cortex (p =−0.22,
p=0.17) or to functional connectivity between the caudate and the an-
terior thalamus (r =−0.04, p = 0.86). Controlling for mean head mo-
tion as a covariate in the analysis increased the correlation betweenDAT
density and putamen–midbrain connectivity to r = 0.44 (p= 0.03).
Seven patients were excluded based on this additional quality con-
trol step. Although the identiﬁcation of these subtle motion artifacts be-
yond the objective thresholds we set for movement parameters, is
somewhat subjective, we ﬁnd it important to demonstrate that for
this sub-sample (N = 13), the correlations of striatal DAT density with
putamen–midbrain connectivity (r = 0.52, p = 0.04) and putamen–
postcentral gyrus (r =−0.50, p = 0.04) were still present. In a further
set of control analyses, age, disease duration, subcortical atrophy, Hoehn
and Yahr stage, and levodopa equivalent dose during the fMRI scan
were explored in this subsample as possible confounding variables of
the association between Altropane DVR and functional connectivity, be-
yond headmotion. Notably, the association between functional connec-
tivity MRI and DAT availability was reduced to trend-level when we
accounted for medication (Table 1) as levodopa equivalent dose shared
an associationwith both DAT availability (r=−0.55, p=0.03) and pu-
tamen functional connectivity estimates (midbrain: r = −0.54, p =
0.03; postcentral gyrus: r = 0.45, p = 0.06). Importantly, however, no
single covariate could fully explain the association between AltropaneFig. 3. Greater striatal DAT availability (Altropane DVR) is related to stronger connectivity o
postcentral gyrus. * = p b .05. Patients with cognitive impairment are highlighted in green. F
for the patients and inspected for remaining movement artifacts in the form of a ring activatio
fMRI data; cf Beckmann et al., 2000; Satterthwaite et al., 2013; White et al., 2014).DVR and functional connectivity, indicating a direct association be-
tween measures of striatal dopamine functions and functional connec-
tivity estimates beyond their shared association with disease severity.
Incidentally, the associations between DAT density and putamen
connectivity estimates were not present in the healthy controls (mid-
brain: r = 0.16, p = 0.21; post-central gyrus: r = −0.01, p = 0.50,
co-varied for mean motion). Rather, in the healthy controls striatal
DAT availability was signiﬁcantly associated with connectivity between
caudate and anterior thalamus (r = 0.35, p = 0.04, co-varied for mean
motion) and, at trend-level, with the connectivity between caudate and
anterior cingulate (r = 0.24, p = 0.11, co-varied for mean motion).
Patients with and without cognitive impairment did not differ signiﬁ-
cantly in any of the functional connectivity estimates (all p values N 0.05)
and because of the limited sample sizewewere unable to assess addition-
al or interacting effects of cognitive impairment in the current study. The
patients with cognitive impairment are highlighted in green in the
scatterplots.4. Discussion
Previous research has shown reductions in functional connectivity
between themidbrain and the putamen in group comparisons between
healthy control subjects and patients with Parkinson3s disease. Al-
though functional connectivity MRI is a popular and reliable method
for assessing the organization of functional networks in the brain, it re-
mains challenging to relate inter-individual differences in connectivity
strength between two regions to the integrity of the underlying neural
pathways.
In the current study, we combined resting state fMRI and PET to
show that individual differences in midbrain–putamen functional con-
nectivity in patients with nigrostriatal dopamine loss are proportionalf the putamen to midbrain and to increasingly negative correlation of the putamen to
or additional quality control, whole-brain functional connectivity maps were generated
n pattern at the edges of the brain (a commonly mentioned residual effect of motion on
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these patients was unrelated to connectivity within the caudate–
thalamic–prefrontal loop. Histopathology studies have shown speciﬁc
losses of dopaminergic nigro-striatal projections in Parkinson3s disease
and dementia with Lewy bodies that are dissociable from normal aging
(Fearnley and Lees, 1991) and our ﬁndings suggest that putamen func-
tional connectivity estimates are sensitive to impairment of this projec-
tion. Pertaining to this point, we found no evidence for an association
between putamen–midbrain connectivity and DAT availability in the
healthy controls. This interpretation does not preclude the possibility
that caudate networks may also play a role in disease progression and
relate to the cognitive impairment that develops in a subset of patients.
Here, wewere unable to disentangle differential patterns of striatal con-
nectivity in patients with and without dementia because of the small
number of cognitively impaired subjects.
Studies applying a levodopa challenge in young adults (Kelly et al.,
2009; Cole et al., 2013) and patients with Parkinson3s disease (Jech
et al., 2013) have shown acute increases inmidbrain functional connec-
tivity following drug administration. Taken together, our results and the
results from pharmacological fMRI studies show that midbrain func-
tional connectivity can be sensitive to the overall trait of the dopamine
system (i.e. striatal DAT availability) as well to as short-term changes in
dopamine state (i.e. following pharmacological intervention). In line
with this, while levodopa dose accounted for a part of the association
between DAT availability and putamen connectivity, levodopa dose
did not fully explain the resting-state functional connectivity estimates
attributable to DAT availability. That said, further research is needed to
validate the usefulness of functional connectivity as a correlate of PET-
based imaging of the dopamine system also in patients off medication
and in very early stages of the disease. In the current study, patients
were in a moderate disease stage and tested on medication to avoid
movement in the scanner and to reduce patient burden. With respect
to accurately disentangling the effects of levodopa dose and DAT avail-
ability on functional connectivity, the fact that all patients were tested
on medication is a potential limitation of the current study.
In addition to midbrain–putamen connectivity, we found that DAT
availability was related to negative correlations between putamen sig-
nal and the postcentral gyrus. Negative correlations are often seen in
resting-state studies of the striatum (e.g. di Martino et al., 2008), and
appear to be less negative in Parkinson3s disease (Göttlich et al., 2013;
Hacker et al., 2012; Wu et al., 2009; Yu et al., 2013), suggesting that pu-
tamen correlations of either sign tend towards zero as striatal dopamine
terminals are lost and the disease progresses (Olde Dubbelink et al.,
2014). Our results conﬁrm that weaker estimates of either sign are re-
lated to the disease process. However, it should be noted that negative
correlations are difﬁcult to interpret in functional connectivity analyses
(Weissenbacher et al., 2009), and it is unclearwhether negative correla-
tions between putamen and postcentral gyrus reﬂect the integrity of an-
atomical projections. As Lewy bodies tend to spare the sensori-motor
cortices until late in the disease (Braak et al., 2004), negative correla-
tions between the putamen and sensori-motor areas may relate to the
neurodegenerative disease process through downstream effects of
nigrostriatal dopaminergic depletion.Of note, awhole-brain explorative
correlational analysis by Baik et al. (2014) suggested that associations
between DAT availability and striatal connectivity may also exist for re-
gions outside of putamen–thalamic–cortical networks, which we did
not assess here.
One limitation of the current study may be that our measure of
striatal DAT availability does not distinguish between caudate and puta-
men or between brain hemispheres. We chose this approach because it
ensures that DVR estimation was fully automated and would not be af-
fected by differences in striatal volume between participants or by errors
in registration, which can be substantial in patient groups (e.g. Reig et al.,
2007). Our striatal estimate of DAT availability accurately distinguished
between patients and normal controls, and measures of DAT availability
correlated with measures of symptom severity as expected.A further limitation of this study is the small sample size, which was
due to a priori screening of patients for head motion during fMRI scan-
ning. Motion is a common problem in fMRI studies of patients with
movement disorders (Hacker et al., 2012), and we opted for analytic
rigor over larger numbers of subjects. We hope that with public data-
bases becoming increasingly available, it will in the future be possible
to replicate our results in a larger independent sample.
In conclusion, this study shows that functional connectivity between
themidbrain and the striatum is linked to the integrity of the dopamine
system in patients with Lewy body diseases. These ﬁndings suggest that
midbrain–striatum functional connectivity may provide a useful indica-
tor of underlying pathology in diseases characterized by nigrostriatal
dopamine loss.
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